Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues

Prostate

Volumn 47, Issue 1, 2001, Pages 14-20

  Björk, Thomas ^a,c   Schalken, Jack ^b   Wittjes, Wim ^b   Ljungberg, Bengt ^a   Lilja, Hans ^a  

^a LUND UNIVERSITY   (Sweden)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

GnRH analogues; Hormonal treatment; Prostate cancer; Prostate specific antigen

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; GONADORELIN DERIVATIVE; GOSERELIN; HUMAN KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CLINICAL ARTICLE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0035313073     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1042     Document Type: Article

References (27)

1. Prostate antigen: A marker for human prostate epithelial cells
2. In situ hybridization of prostate-specific antigen mRNA in human prostate
3. Production of alpha-1-antichymotrypsin by PSA-containing cells of the human prostate epithelium
4. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes
5. Characterization of the human kallikrein locus
6. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
7. Primary structure of a human glandular kallikrein gene
8. Mechanism of zymogen activation
9. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2
10. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein
11. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors
12. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer
13. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
14. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
15. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
16. Rapid exponential elimination of free prostate-specific antigen (PSA) contrasts the slow, capacity-limited elimination of PSA complexed to alpha-1-antichymotrypsin from serum
17. A randomized trial comparing the safety and efficiacy of the Zoladex 10.8-mg depot, administered every 12 weeks to that of the Zoladex 3.6-mg depot administered every 4 weeks, in patients with prostate cancer
18. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha-1-antichymotrypsin complex
19. Comparability of the tandem-R and Imx assays for the measurement of serum prostate-specific antigen
20. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum
21. Clinical utility of a novel highly sensitive and specific assay for human prostatic glandular kallikrein (hK2) in serum
22. A high ratio of free to total prostate specific is predominant in biochemical relapse of prostate cancer after radical prostatectomy
23. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
24. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial
25. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue
26. Production and characterization of novel antiprostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved lys145-lys146 inactive PSA